Skip to main content

Table 2 Treatment characteristics of study participants

From: Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service – results from the prospective, multi-center, observational cohort study thrombEVAL

Characteristic Regular medical care Coagulation service
Total amount of treatment days 4,681,125 931,579
Total amount of international normalized ratio (INR) values 29,748 19,207
Median time between INR measurements [days; interquartile range] 17.0 (10.7/26.0) 15.2 (11.4/18.8)
Self-management of oral anticoagulant therapy 13.5 (271) 9.5 (72)
Physician in charge   
General practitioner, % (no.) 67.6 (1,359) n.a.*
Specialist, % (no.) 32.3 (650) n.a.*
Home visits, % (no.) 6.8 (137) 8.8 (67)
Vitamin K antagonist in use   
Warfarin, % (no.) 1.7 (34) 1.7 (13)
Phenprocoumon, % (no.) 98.3 (1,977) 98.3 (747)
  1. Data are expressed as the relative and absolute frequencies for binary variables. *Due to management of anticoagulation in the coagulation service classification of “physician in charge” was not applicable in these patients.